Canntab Therapeutics Limited

Equities

PILL

CA1377991023

Pharmaceuticals

Market Closed - Canadian Securities Exchange 02:07:30 2023-10-04 pm EDT 5-day change 1st Jan Change
0.005 CAD -.--% Intraday chart for Canntab Therapeutics Limited -.--% -.--%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Canntab Therapeutics Limited announced that it expects to receive CAD 0.1 million in funding CI
Canntab Therapeutics Limited Provide an Update on Product Delivery CI
Canntab Therapeutics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023 CI
Canntab Therapeutics Limited Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2022 CI
Canntab Therapeutics Limited Reports Earnings Results for the First Quarter Ended August 31, 2022 CI
Canntab Therapeutics Limited Auditor Raises 'Going Concern' Doubt CI
Canntab Therapeutics Limited Reports Earnings Results for the Full Year Ended May 31, 2022 CI
Canntab Therapeutics on Entrance Into the Nova Scotia Cannabis Market MT
Canntab Therapeutics Limited Announces Chief Executive Office Changes CI
Canntab Therapeutics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2022 CI
Canntab Therapeutics Limited Receives Approval from the Province of Saskatchewan to Begin Sales CI
Canntab Therapeutics Limited Enters into Affiliate Agreement with Onpharm-United CI
Canntab Therapeutics Limited Signs Historic Agreement with First Nations Growers Gp Inc. to Address the Opiate and Illicit Drug Crisis Affecting Indigenous Peoples Throughout Canada CI
Canntab Therapeutics Limited announced that it has received CAD 1.312 million in funding CI
Canntab Therapeutics Limited Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2021 CI
Canntab Therapeutics Limited Officially Launches its Online E-Commerce Platform CI
Levitee Labs Inc. Enters into A Strategic Partnership Via A Services Agreement with Canntab Therapeutics Limited CI
Canntab Delivers 1st Shipment to the Ontario Cannabis Store and 2nd Shipment to Australia CI
Canntab Enters into Strategic Partnership to Provide Alternatives to Opiates Through Levitee Clinics CI
Pathway Health Corp. Announces Agreement with Canntab Therapeutics Limited CI
Canntab Therapeutics Limited Announces Agreement with Pathway Health CI
Health Canada Awards Medical Sales Licence to Canntab MT
Canntab Receives Medical Sales License from Health Canada CI
Canntab Therapeutics Limited Reports Earnings Results for the First Quarter Ended August 31, 2021 CI
Canntab Reaches Agreement with 36eight Technologies Inc CI
Chart Canntab Therapeutics Limited
More charts
Canntab Therapeutics Limited is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The Company’s operations comprise a single segment engaged in the medical marijuana business. The Company’s hard pill cannabinoid formulations provide doctors, patients, and consumers with medical grade solutions. These include once a day and extended-release formulations. Its products include INSTANT RELEASE - (IR Tablet), EXTENDED-RELEASE - (XR Tablet), and ORAL DISSOLVING - O.D. Tablet (ODT). The IR Tablet is a release profile for solid hard tablets. The XR Tablet is a phytocannabinoid vehicle that is designed to directly address the drawbacks and challenges of competing oral delivery systems. ODT is specifically designed to dissolve directly in the patient’s mouth, with an onset of action between five and thirty minutes.
More about the company
  1. Stock Market
  2. Equities
  3. PILL Stock
  4. News Canntab Therapeutics Limited
  5. Canntab Therapeutics on Entrance Into the Nova Scotia Cannabis Market